Better Health for All

AnaptysBio's core business is developing antibody therapeutics for severe, chronic, rare, or life-threatening autoimmune, inflammatory, and oncology diseases, indicating a portfolio delivering revolutionary health benefits. Its licensed product, JEMPERLI, received FDA approval in April 2021 for advanced or recurrent deficient mismatch repair endometrial cancer and in August 2021 for pan-deficient mismatch repair tumors, also receiving conditional EMA marketing authorization.

Rosnilimab has shown positive Phase 2b results in rheumatoid arthritis, demonstrating rapid clinical and symptomatic improvement, and imsidolimab achieved significant skin clearance in Phase 3 trials for generalized pustular psoriasis (GPP). Rosnilimab's Phase 2b trial in rheumatoid arthritis reported no treatment-related serious adverse events or malignancies in over 185 patient years of exposure, and adverse event rates were similar to placebo. Imsidolimab's Phase 3 trials also showed a consistent, favorable safety and tolerability profile with no treatment-related serious adverse events. However, one patient in an imsidolimab trial dropped out due to Staphylococcal aureus bacteremia, deemed possibly drug-related. The company's products target rare diseases like GPP, which affects approximately 3,000 patients in the U.S., and hidradenitis suppurativa, affecting about 150,000 U.S. adults. Rosnilimab's Phase 2b trial for rheumatoid arthritis enrolled 424 patients across the U.S., Canada, and Europe, including both b/tsDMARD naïve (59%) and experienced (41%) patients. The company provides risk factor disclosures and forward-looking statement warnings in its investor documents. AnaptysBio has devoted its primary effort to research and development activities since inception, with R&D expenses of $163.8 million for the full year 2024. The company states compliance with HIPAA and GDPR regulations. Clinical trials are conducted in accordance with general investigational plans and protocols, relying on third-party clinical investigators and CROs. The company has out-licensed JEMPERLI and imsidolimab, with JEMPERLI receiving Breakthrough Therapy Designation in December 2024, and imsidolimab receiving Orphan Drug Designation for GPP in July 2020, which may provide market exclusivity. AnaptysBio is an equal opportunity and affirmative action employer, committed to equal employment opportunity regardless of various protected characteristics. The company offers an on-site fitness center and company-provided meals to employees. AnaptysBio offers comprehensive medical, dental, and vision coverage, an employee assistance program, and tuition reimbursement benefits for its employees.

Fair Pay & Worker Respect

AnaptysBio offers comprehensive medical coverage options for employees and their dependents.

The company also provides comprehensive dental and vision coverage at no cost to employees. Additionally, an Employee Assistance Program is available, which typically includes mental health services. Employees receive a 10% 401k match, new hire and annual equity grants via stock options and RSUs, an Employee Stock Purchase Plan, and tuition reimbursement benefits. The company also offers generous time off, including 15 vacation days per year, company holidays, and a winter closure.

Fair Trade & Ethical Sourcing

The provided articles, including the company's 2023 Form 10-K, a Sustainalytics report, the company's Terms of Use, and an auditor's report, do not contain any quantitative data or specific information relevant to AnaptysBio, Inc.'s fair trade and ethical sourcing practices.

There is no evidence regarding fair trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.

Honest & Fair Business

AnaptysBio has a formal Whistleblower Policy for confidential and anonymous submission of concerns regarding accounting, internal accounting controls, or auditing matters by company employees.

The Audit Committee oversees the review of these complaints and determines the appropriate response and remedy, but there is no explicit evidence of independent investigation processes beyond this oversight. The company's Form 10-Q for September 30, 2025, does not mention any financial restatements, and no other article indicates restatements in the past five years, suggesting no recent formal restatements. The Audit Committee charter states that each member must be free from relationships that would interfere with independent judgment, but it does not provide a specific percentage of conflict-free board members.

Kind to Animals

AnaptysBio conducts pre-clinical studies on animals to assess drug safety, with its pipeline of antibodies tested in animal models.

However, the provided article does not offer specific data points on the company's animal testing policy, the volume of animals used, alternative testing methods, or any other animal welfare metrics to allow for scoring against the rubric's KPIs.

No War, No Weapons

AnaptysBio's SHM-XEL platform has dual-use potential, capable of generating antibodies for both therapeutic and biodefense applications.

The company received a contract from the U.S. government for anti-ricin antibody development, funded by the Defense Threat Reduction Agency (DTRA). Additionally, AnaptysBio partnered on DARPA's Antibody Technology Program for antibody-based biosensors for biological warfare agent detection, with these advancements intended for military deployment.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles to assess AnaptysBio, Inc. against the defined KPIs for 'Respect for Cultures & Communities'. The articles primarily focus on financial performance, corporate structure, and employee-centric benefits, without detailing community engagement, cultural impact assessments, or specific charitable giving to cultural heritage organizations.

Information regarding partnerships, local investment, cultural incidents, or community grievance mechanisms is not present.

Safe & Smart Tech

AnaptysBio's Global Privacy Policy states that users can request information about how their data is collected and used, access copies, correct inaccuracies, delete data, and withdraw consent where applicable.

The policy also indicates that data is collected only as necessary and retained as long as needed for business purposes and legal requirements. Furthermore, the policy mentions compliance with applicable laws, including HIPAA for protected health information. The company's 10-K filing notes a collaborative, cross-functional approach to cybersecurity risk management, overseen by the Audit Committee, and mentions the use of a managed detection and response partner, security consultants, and a vCISO. Technical safeguards such as firewalls, intrusion prevention/detection systems, anti-malware, and access controls are in place, along with third-party risk management and employee training. However, no specific quantitative data or metrics are provided for the effectiveness of these measures, nor for other KPIs such as data breach severity, cybersecurity investment, privacy certifications, security training effectiveness, encryption implementation, AI ethics governance, AI audit practices, algorithmic transparency, unauthorized data use, authentication security, vulnerability management, bug bounty effectiveness, privacy by design, security testing coverage, algorithmic harm remediation, or digital rights advocacy.

Zero Waste & Sustainable Products

No specific, quantitative data was found across any of the provided articles to assess AnaptysBio, Inc. against the 'Zero Waste & Sustainable Products' value.

While an employee-led initiative to collect and recycle nitrile gloves was mentioned, the information explicitly stated a lack of specific data or metrics to assess its impact on waste reduction or sustainability, preventing any KPI from being scored.